These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37522355)

  • 1. Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: A multicenter matched cohort study.
    Liu TH; Chuang MH; Wu JY; Huang PY; Tsai YW; Hsu WH; Lai CC
    J Med Virol; 2023 Aug; 95(8):e28992. PubMed ID: 37522355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19.
    Wu JY; Liu MY; Liu TH; Chuang MH; Hsu WH; Huang PY; Tsai YW; Lai CC
    Int J Antimicrob Agents; 2023 Dec; 62(6):106984. PubMed ID: 37769748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    Tsai YW; Wu JY; Liu TH; Chuang MH; Hsu WH; Huang PY; Lai CC; Tsai KT; Shiue YL
    J Med Virol; 2023 Jun; 95(6):e28869. PubMed ID: 37322616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19.
    Liu TH; Wu JY; Huang PY; Tsai YW; Lai CC
    J Med Virol; 2023 Jul; 95(7):e28951. PubMed ID: 37436873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    Wu JY; Chen CC; Liu MY; Hsu WH; Tsai YW; Liu TH; Pin-Chien S; Huang PY; Chuang MH; Lee MC; Hung KC; Yu T; Lai CC
    J Med Virol; 2024 May; 96(5):e29662. PubMed ID: 38727085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19.
    Wu JY; Liu MY; Liu TH; Chuang MH; Hsu WH; Huang PY; Tsai YW; Kuo CY; Yeh CT; Lai CC
    J Med Virol; 2023 Jun; 95(6):e28866. PubMed ID: 37314228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases.
    Liu TH; Wu JY; Huang PY; Hsu WH; Chuang MH; Tsai YW; Lai CC; Huang CY
    Expert Rev Anti Infect Ther; 2024; 22(1-3):121-128. PubMed ID: 37965890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019.
    Ganatra S; Dani SS; Ahmad J; Kumar A; Shah J; Abraham GM; McQuillen DP; Wachter RM; Sax PE
    Clin Infect Dis; 2023 Feb; 76(4):563-572. PubMed ID: 35986628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years.
    Faust JS; Kumar A; Shah J; Khadke S; Dani SS; Ganatra S; Sax PE
    Clin Infect Dis; 2023 Nov; 77(9):1257-1264. PubMed ID: 37387690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis.
    Hsu WH; Shiau BW; Liu TH; Wu JY; Tsai YW; Huang PY; Chuang MH; Lai CC; Chen CH
    Expert Rev Anti Infect Ther; 2023; 21(10):1143-1151. PubMed ID: 37795869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID-19 and substance use disorders based on real-world data.
    Liu TH; Huang PY; Wu JY; Chuang MH; Hsu WH; Tsai YW; Chang CC; Lai CC
    J Med Virol; 2023 May; 95(5):e28801. PubMed ID: 37218308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection.
    Chuang MH; Wu JY; Liu TH; Hsu WH; Tsai YW; Huang PY; Lai CC
    J Med Virol; 2023 Apr; 95(4):e28750. PubMed ID: 37185834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
    Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
    JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease.
    Chen CC; Huang CY; Wu JY; Liu MY; Chuang MH; Liu TH; Tsai YW; Hsu WH; Huang PY; Chen MH; Liu SY; Lee MC; Hung KC; Lai CC; Yang IN
    Expert Rev Anti Infect Ther; 2024 Aug; 22(8):705-712. PubMed ID: 38525673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).
    Yip TC; Lui GC; Lai MS; Wong VW; Tse YK; Ma BH; Hui E; Leung MKW; Chan HL; Hui DS; Wong GL
    Clin Infect Dis; 2023 Feb; 76(3):e26-e33. PubMed ID: 36031408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study.
    Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB
    J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
    Butt AA; Yan P; Shaikh OS
    PLoS One; 2024; 19(6):e0298254. PubMed ID: 38843201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.